Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Wedbush Analyst Says

Opus Genetics (NASDAQ:IRD) had its price target increased by research analysts at Wedbush from $10.00 to $13.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 126.88% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. Royal Bank Of Canada decreased their price target on shares of Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Oppenheimer raised their target price on shares of Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Guggenheim assumed coverage on shares of Opus Genetics in a report on Thursday, June 4th. They set a “buy” rating and a $16.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.92.

Opus Genetics Stock Up 32.0%

Shares of IRD stock opened at $5.73 on Thursday. The stock has a market cap of $473.58 million, a price-to-earnings ratio of -4.24 and a beta of 0.58. The business’s fifty day moving average is $3.82 and its 200 day moving average is $4.30. Opus Genetics has a twelve month low of $1.32 and a twelve month high of $7.07.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $2.63 million. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%. Equities research analysts expect that Opus Genetics will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Robert Gagnon sold 28,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total value of $127,120.00. Following the transaction, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at approximately $2,525,942.50. This represents a 4.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of the stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. This represents a 0.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 57,331 shares of company stock valued at $213,749. 11.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Opus Genetics

Several large investors have recently bought and sold shares of IRD. BlackRock Inc. purchased a new stake in shares of Opus Genetics during the 2nd quarter valued at about $12,809,000. Nantahala Capital Management LLC bought a new stake in shares of Opus Genetics in the second quarter worth approximately $12,582,185. Trails Edge Capital Partners LP purchased a new position in shares of Opus Genetics during the second quarter valued at approximately $11,276,434. Balyasny Asset Management L.P. purchased a new position in shares of Opus Genetics during the fourth quarter valued at approximately $5,463,000. Finally, Millennium Management LLC purchased a new position in shares of Opus Genetics during the fourth quarter valued at approximately $4,025,000. 14.97% of the stock is currently owned by institutional investors.

Opus Genetics News Summary

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics reported positive results from the low-dose cohort of its Phase 1/2 BIRD-1 trial. All five participants showed clinically meaningful visual-function improvement, with no serious adverse events or dose-limiting toxicities; improvements in visual acuity were observed in three participants. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: The company said a successful FDA Type C meeting provided alignment on a potential pivotal endpoint involving microperimetry improvement and patient-reported outcomes. Cohort 2 was over-enrolled, with dosing expected to finish in the fourth quarter of 2026 and three-month data targeted for the second quarter of 2027. Opus Genetics Reports Positive OPGx-BEST1 Data
• Positive Sentiment: Analysts raised their valuations and maintained bullish ratings: Wedbush increased its target to $13 from $10, Oppenheimer raised its target to $20 from $10, while BTIG, Chardan and HC Wainwright maintained Buy ratings with targets of $12, $13 and $8, respectively. Wedbush Raises Opus Genetics Price Target
• Positive Sentiment: Unusually heavy call-option buying—4,820 contracts versus typical volume of about 617—signaled increased speculative interest following the clinical update.
• Neutral Sentiment: Management expects cash resources to support operations into 2029, potentially funding several upcoming clinical milestones and reducing near-term financing concerns.
• Negative Sentiment: CFO Robert Gagnon sold 28,000 shares valued at $127,120. The filing said the transaction was made to cover tax withholding tied to vested equity awards, limiting its negative significance, though it remains an insider-sale signal. Opus Genetics CFO Stock Sale

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.